Medtronic Self-expanding TAVR Platform Shows Excellent Longer-term Performance at 5 Years in SURTAVI Trial

TCT 2021: Intermediate risk TAVR patients demonstrate strong hemodynamics and stable valve performance at five years

Medtronic plc (NYSE:MDT), a global leader in healthcare technology, today unveiled five-year clinical data from the Surgical Replacement and Transcatheter Aortic Valve Implantation (SURTAVI) Trial, which was presented as a Late Breaking Clinical Trial at the 33rd Transcatheter Cardiovascular Therapeutics (TCT) conference, the annual scientific symposium of the Cardiovascular Research Foundation.

Data from the trial showed that the hemodynamic (blood flow) benefits of the Medtronic CoreValve™ and Evolut™ platforms were maintained at five years with an excellent safety profile and stable valve performance in patients with symptomatic, severe aortic stenosis who are at an intermediate risk for open-heart surgery.

At five years, rates of all-cause mortality were similar between TAVR with the CoreValve/Evolut platform and surgical aortic valve replacement (SAVR) (30.0% for TAVR versus 28.7% for SAVR; p=0.55), while rates of disabling stroke were also similar (4.1% for TAVR versus 5.8% for SAVR, p = 0.12). The TAVR arm continued to demonstrate durable valve longevity, as evidenced by better mean aortic valve gradients (8.6 mm Hg vs. 11.2 mm Hg; p<0.001) at five years. Additionally, valve thrombosis remained low out to five years for both TAVR and SAVR.

In the study, patients considered to be at intermediate risk for open-heart surgery had a risk of mortality of ≥ 3 and < 15% at 30 days following the procedure in combination with other factors.

“TAVR has revolutionized the treatment of aortic stenosis with more TAVR cases now performed than surgical aortic valve replacement for this disease. With this shift in treatment, longer-term, randomized data is increasingly important as we strive to better understand the lifetime management of these patients,” said Michael Reardon, M.D., professor of cardiothoracic surgery and Allison Family Distinguished Chair of Cardiovascular Research at Houston Methodist DeBakey Heart & Vascular Center, principal investigator in the SURTAVI trial.

The global, prospective, multi-center, randomized SURTAVI Trial evaluated two early valve generations (CoreValve™, Evolut™ R) across a variety of valve sizes in 864 intermediate-risk symptomatic severe aortic stenosis patients. Patients in the TAVR arm were compared to 796 intermediate-risk patients who were randomized to open-heart surgery.

“These longer-term outcomes are remarkably similar after TAVR and surgery in patients with severe aortic stenosis at intermediate operative risk,” said Nicolas Van Mieghem, M.D., Ph.D., professor of interventional cardiology, department of cardiology, Thoraxcenter, Erasmus University Medical Center in Rotterdam, The Netherlands, who presented the data at the meeting. “Additionally, results from this study are particularly impressive given the TAVR devices evaluated were first- and second-generation systems.”

The Evolut TAVR platform, which includes the Evolut™ R, Evolut™ PRO, Evolut™ PRO+, and newest-generation Evolut™ FX valves, is indicated for symptomatic severe aortic stenosis patients across all risk categories (extreme, high, intermediate and low) in the U.S.

SourceMedtronic
Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides our readership with breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

The ArthroFree system is the first FDA-cleared wireless camera for arthroscopy and general endoscopy, both areas of minimally invasive surgery. The system is designed to help surgeons work with aximum dexterity and focus.
The project, which was led by the University of Southern California, included large increases in representation among men of African, Hispanic and Asian ancestries, that were contributed in part by an ongoing collaboration between the U.S. Department of Veterans Affairs and DOE reports Argonne.
This innovative software turns smartphones into medical-grade stethoscopes, allowing people to capture, analyze, and share critical heart health data with medical personnel from the comfort of any location notes Sparrow BioAcoustics.
"Taewoong Medical becoming an Olympus group company is also a major milestone in our global growth strategy," said Henry Shin, CEO of STARmed. "We look forward to our products being made available to more patients through Olympus' global distribution network."
The company reports they have successfully met the six-month primary endpoint for the first-ever female patient implanted with the UroActive™ System, the first smart automated artificial urinary sphincter (AUS) to treat SUI.

By using this website you agree to accept Medical Device News Magazine Privacy Policy